Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026. The company will hold a conference call beginning ...

This royalty-focused biotech with a broad drug portfolio reported a notable insider sale amid strong stock performance.

FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failureLigand is entitled to a 9% ...

Ligand’s strategy of providing development capital to high-quality assets with capable teams is paying off, as evidenced by the recent positive developments and advancements in its product pipeline.

Ligand Pharmaceuticals sees its Relative Strength Rating hit the elite 90-plus level.

Ligand Pharmaceuticals (LGND) is a royalty investor in late-stage biopharma, with revenue and EPS growth driven by a robust portfolio. LGND expects royalty revenue to compound at a 23% CAGR through ...

The FDA had extended the review of its supplemental New Drug Application for Filspari in January 2026. ・Citi kept a $48 price target for Travere, adding that it expects the FDA to approve the drug.

Ligand Pharmaceuticals was ready to spin off its antibody discovery wing into a new company when special purpose acquisition company Avista Public Acquisition Corp. came knocking. So now, a month ...

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating ...